Sterling to receive TFT arrays from OIS

Article

Sterling Diagnostic Imaging has announced that a supply of thin-film transistor (TFT) arrays for its iiRad with DirectRay digital x-ray systems has been assured into the second quarter of 1999. The Greenville, SC-based company reached a settlement with

Sterling Diagnostic Imaging has announced that a supply of thin-film transistor (TFT) arrays for its iiRad with DirectRay digital x-ray systems has been assured into the second quarter of 1999. The Greenville, SC-based company reached a settlement with OIS (Optical Imaging Systems) that will enable Sterling to gain access to all the TFT arrays at OIS, which recently announced it had shut its doors when its primary investor withdrew funding (SCAN 10/14/98). Sterling will also receive work-in-progress arrays from OIS, according to Sterling.

Meanwhile, the company is having encouraging discussions with several alternative TFT suppliers that could result in resumed production of TFT panels for Sterling by mid-1999, said Ernest Waaser, COO. This would result in minimal impact on supply of iiRad with DirectRay systems, he said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.